CN104080910A - 使用微rna195提供神经保护作用的方法 - Google Patents

使用微rna195提供神经保护作用的方法 Download PDF

Info

Publication number
CN104080910A
CN104080910A CN201280053577.8A CN201280053577A CN104080910A CN 104080910 A CN104080910 A CN 104080910A CN 201280053577 A CN201280053577 A CN 201280053577A CN 104080910 A CN104080910 A CN 104080910A
Authority
CN
China
Prior art keywords
mirna
mir
neuroprotective
disease
microrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280053577.8A
Other languages
English (en)
Chinese (zh)
Inventor
卓夙航
王永松
郑欣芸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kaohsiung Medical University
Original Assignee
Kaohsiung Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaohsiung Medical University filed Critical Kaohsiung Medical University
Publication of CN104080910A publication Critical patent/CN104080910A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN201280053577.8A 2011-11-03 2012-11-05 使用微rna195提供神经保护作用的方法 Pending CN104080910A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161555152P 2011-11-03 2011-11-03
US61/555,152 2011-11-03
PCT/US2012/063604 WO2013067531A2 (en) 2011-11-03 2012-11-05 Methods of using microrna 195 in providing neuroprotection

Publications (1)

Publication Number Publication Date
CN104080910A true CN104080910A (zh) 2014-10-01

Family

ID=48193054

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280053577.8A Pending CN104080910A (zh) 2011-11-03 2012-11-05 使用微rna195提供神经保护作用的方法

Country Status (7)

Country Link
US (1) US9315812B2 (2)
EP (1) EP2773381B1 (2)
JP (1) JP5888572B2 (2)
CN (1) CN104080910A (2)
IN (1) IN2014DN03464A (2)
TW (1) TWI462741B (2)
WO (1) WO2013067531A2 (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113308535A (zh) * 2021-06-11 2021-08-27 中国人民解放军空军军医大学 一种基于血清外泌体miRNA的PD诊断及分期试剂盒
CN113599540A (zh) * 2021-05-27 2021-11-05 山西医科大学 miRNA-195-5p在抑制或降低麦芽酚铝所致神经细胞损伤中的应用
WO2022033529A1 (zh) * 2020-08-12 2022-02-17 洪明奇 Sema3d拮抗剂在预防或治疗神经退行性疾病以及延长寿命中的用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9758782B2 (en) * 2013-06-28 2017-09-12 London Health Sciences Centre Research Inc. Inhibition of microRNA for treatment of sepsis
CN106474549B (zh) * 2016-11-21 2019-05-03 南通大学 MicroRNA基因介导的新型组织工程化神经的构建及其在修复神经缺损的应用
WO2018111784A1 (en) * 2016-12-14 2018-06-21 China Medical University Micro-rna-195 compositions and therapeutic use in ocular diseases
US20230070049A1 (en) * 2020-02-03 2023-03-09 Rutgers, The State University Of New Jersey Microrna-7 compositions for promoting functional recovery following spinal cord injury and methods of use thereof
CN116590403B (zh) * 2023-05-17 2024-11-22 华中科技大学同济医学院附属同济医院 血浆外泌体microRNA novel-3及其拮抗剂和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261218A1 (en) * 2003-07-31 2005-11-24 Christine Esau Oligomeric compounds and compositions for use in modulation small non-coding RNAs
US20100317713A1 (en) * 2007-11-09 2010-12-16 Eric Olson Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
WO2010151640A2 (en) * 2009-06-24 2010-12-29 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
TW201120218A (en) * 2009-12-10 2011-06-16 Univ Kaohsiung Medical Composition for treating atherosclerosis, use of microRNA-195, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP2295604B1 (en) * 2004-02-09 2015-04-08 Thomas Jefferson University Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features
US20100298407A1 (en) * 2007-01-17 2010-11-25 The Johns Hopkins University Compositions and methods featuring micronas for treating neoplasia
US20110117111A1 (en) * 2008-03-26 2011-05-19 Johns Hopkins University Microrna-based diagnostic testing and therapies for inflammatory bowel disease and related diseases
EP2112235A1 (en) 2008-04-24 2009-10-28 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma
EP2239675A1 (en) * 2009-04-07 2010-10-13 BIOCRATES Life Sciences AG Method for in vitro diagnosing a complex disease

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050261218A1 (en) * 2003-07-31 2005-11-24 Christine Esau Oligomeric compounds and compositions for use in modulation small non-coding RNAs
US20100317713A1 (en) * 2007-11-09 2010-12-16 Eric Olson Micro-rnas of the mir-15 family modulate cardiomyocyte survival and cardiac repair
WO2010151640A2 (en) * 2009-06-24 2010-12-29 Board Of Regents Of The University Of Nebraska Compositions and methods for the diagnosis and treatment of inflammatory disorders and fibrotic disease
TW201120218A (en) * 2009-12-10 2011-06-16 Univ Kaohsiung Medical Composition for treating atherosclerosis, use of microRNA-195, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NAI-KUI LIU AND XIAO-MING XU: "MicroRNA in central nervous system trauma and degenerative disorders", 《PHYSIOL GENOMICS》 *
SOON-TAE LEE ET AL: "MicroRNAs Induced During Ischemic Preconditioning", 《STROKE》 *
TAKAYUKI KAWANO ET AL.: "Prostaglandin E2 EP1 receptors:downstream effectors of COX-2 neurotoxicity", 《NATURE MEDICINE》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022033529A1 (zh) * 2020-08-12 2022-02-17 洪明奇 Sema3d拮抗剂在预防或治疗神经退行性疾病以及延长寿命中的用途
CN113599540A (zh) * 2021-05-27 2021-11-05 山西医科大学 miRNA-195-5p在抑制或降低麦芽酚铝所致神经细胞损伤中的应用
CN113599540B (zh) * 2021-05-27 2023-05-23 山西医科大学 miRNA-195-5p在制备抑制或降低麦芽酚铝所致神经细胞损伤的试剂中的应用
CN113308535A (zh) * 2021-06-11 2021-08-27 中国人民解放军空军军医大学 一种基于血清外泌体miRNA的PD诊断及分期试剂盒

Also Published As

Publication number Publication date
US20140294943A1 (en) 2014-10-02
JP2014533248A (ja) 2014-12-11
US9315812B2 (en) 2016-04-19
IN2014DN03464A (2) 2015-06-05
EP2773381A4 (en) 2015-07-08
EP2773381A2 (en) 2014-09-10
WO2013067531A2 (en) 2013-05-10
EP2773381B1 (en) 2020-06-03
TW201322987A (zh) 2013-06-16
TWI462741B (zh) 2014-12-01
WO2013067531A3 (en) 2014-07-03
JP5888572B2 (ja) 2016-03-22

Similar Documents

Publication Publication Date Title
CN104080910A (zh) 使用微rna195提供神经保护作用的方法
CN102803284B (zh) 用于miRNA抑制剂和模拟物的化学修饰基序
US9255268B2 (en) Methods for diagnosing and treating learning or mental disorders
TW202012624A (zh) 用以調節atxn2 表達之寡核苷酸
WO2010120969A1 (en) Targeting of the mir-30 family and let-7 family as a treatment for heart disease
US11497762B2 (en) MiRNA molecule, equivalent, antagomir, or source thereof for treating and/or diagnosing a condition and/or a disease associated with neuronal deficiency or for neuronal (re)generation
JP7360170B2 (ja) 虚血病変部位特異的な遺伝子治療法
CN116096420A (zh) 利用miR-33b抑制物质的动脉瘤的预防或治疗
KR101783444B1 (ko) miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법
JP2021534759A (ja) Ｍｉｃｒｏｒｎａ−１３４バイオマーカー
Preethi et al. Therapeutic aspect of microRNA inhibition in various types of hypertension and hypertensive complications
EP3793685A1 (en) Pharmaceutical compositions for treatment of microrna related diseases
TW202546228A (zh) 用於抑制胰島素樣生長因子１受體表達的ｒｎａ抑制劑
WO2024165603A1 (en) Pharmaceutical composition for use in treatment of venous thromboembolism
WO2025067482A1 (zh) 调控atxn2表达的dsrna分子
KR20260040626A (ko) 안지오텐시노겐을 표적으로 하는 올리고뉴클레오티드 및 이의 용도
EP4677090A2 (en) Compositions and methods for modulating c3
WO2026067655A1 (zh) 调控TAU表达的dsRNA分子
Zummo The role of circulating and exosomal miRNAs as biomarkers of drug-resistant epilepsy
WO2026002220A1 (zh) 调控TTR表达的dsRNA分子

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141001